PETER TCHERNYCH, NEW DIRECTOR FOR BIOHIT'S DIAGNOSTICS BUSINESS
BIOHIT OYJ STOCK EXCHANGE RELEASE 14 MAY 2009 AT 5:00 PM
PETER TCHERNYCH, NEW DIRECTOR FOR BIOHIT'S DIAGNOSTICS BUSINESS
Peter Tchernych, MSc. econ., LL.M., (52), has been appointed Director of Biohit
Oyj's diagnostic business segment as of 1st June 2009.
Prior to joining Biohit, Mr Tchernych has been working for GE Healthcare, most
recently as Managing Director, Market Development in GE Healthcare
International. He has almost 20 years experience from different sales, marketing
and business development leadership positions within the healthcare technology
industry.
Mr Tchernych was also member of the Board of Biohit Oyj during 2003-2007.
Further information:
Osmo Suovaniemi, M.D., Ph.D., Professor
President & CEO
Tel: +358-9-773 861
Email: osmo.suovaniemi@biohit.com
Jussi Heiniö, VP Administration & Legal Affairs
Tel: +358-9-773 861
Email: jussi.heinio@biohit.com
Distribution:
NASDAQ OMX Helsinki Oy
Central storage facility (www.oam.fi)
Press
www.biohit.com
About Biohit Oyj
Biohit Oyj develops, manufactures and markets liquid handling products and
diagnostic test systems for use in research, health care and industrial
laboratories.
Liquid handling products include electronic and mechanical pipettes and
dispensers, and disposable tips, as well as pipette maintenance and calibration
services. Diagnostics business comprises products and analysis systems for
diagnosing, screening and prevention of gastrointestinal diseases, e.g. the
blood-sample based GastroPanel and GastroView, for diagnosing diseases of the
stomach and associated risks, as well as quick tests for the diagnosis of
lactose intolerance, H. pylori infection and fecal occult blood.
Biohit Oyj is headquartered in Finland. Biohit has subsidiaries in France,
Germany, the UK, Russia, China, Japan and the USA. Additionally, Biohit's
products are sold by approximately 450 distributors in 70 countries. Biohit's
share (BIOBV) is quoted on NASDAQ OMX Helsinki.
Read more at www.biohit.com